Japan’s 1st Avastin Biosimilar Could Get Listing as Early as November; Lilly’s EGFR Up for MHLW Panel Review

The Japanese health ministry will report its plan to approve the country’s first Avastin (bevacizumab) biosimilar at its key panel meeting on April 19, which - if all goes smoothly - will clear the way for its approval in June...read more